infliximab-abda 100 MG Injection

RxCUI: 1927285
RxNorm name: infliximab-abda 100 MG Injection
Display name: infliximab-abda 100 MG Injection
Full name: infliximab-abda 100 MG Injection
Term type: SCD
Status: DailyMed mapping
Updated: 2026-06-04 23:38:54

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
761054	Renflexis	infliximab-abda	351(k) Biosimilar	Rx	2026-08-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Renflexis	INFLIXIMAB	Organon LLC	dbf738c4-3fac-4422-a9d8-51d9c83a8789	2026-08-28	Boxed warning, Warnings, Adverse reactions	Exact identifier rxcui: 1927285

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 2 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
3827e1be-f328-45f7-b113-311b57039f8c	inFLIXimab-abda 100 MG Injection [PSN] · infliximab-abda 100 MG Injection [SCD]	2	14	These highlights do not include all the information needed to use RENFLEXIS safely and effectively. See full prescribing information for RENFLEXIS. RENFLEXIS (infliximab-abda) for injection, for intravenous use Initial U.S. Approval: 2017 RENFLEXIS (infliximab-abda) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differe	20230126
dbf738c4-3fac-4422-a9d8-51d9c83a8789	inFLIXimab-abda 100 MG Injection [PSN] · infliximab-abda 100 MG Injection [SCD]	2	6	These highlights do not include all the information needed to use RENFLEXIS ® safely and effectively. See full prescribing information for RENFLEXIS. RENFLEXIS (infliximab-abda) for injection, for intravenous use Initial U.S. Approval: 2017 RENFLEXIS (infliximab-abda) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful diffe	20251105